AKUMS — Akums Drugs and Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapNeutral

Annual income statement for Akums Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	PROSPECTUS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	27,226	36,719	36,548	41,782	41,182
Cost of Revenue
Gross Profit	9,304	11,838	11,999	14,352	16,847
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	25,106	33,724	35,375	38,478	37,943
Operating Profit	2,120	2,995	1,174	3,304	3,239
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,723	-1,932	1,503	-453	3,453
Provision for Income Taxes
Net Income After Taxes	1,234	-2,509	978	7.9	3,438
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,227	-2,525	949	-40.4	3,382
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,227	-2,525	949	-40.4	3,382
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	8.27	-15.5	8.83	0.826	21.5
Dividends per Share